Intrinsiqq
Eikon Therapeutics Inc. logo

Eikon Therapeutics Inc. Financials

EIKN

⊜ Compare

All currency values in $ millions unless otherwise noted

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
Revenues
Revenue$0$0$0$0
Operating Income-$339-$339-$260-$266
Non-Operating
Net Interest Expense–-$1-$0-$0
Net Income
Net Income-$322-$324-$244-$242
Per Share Data
Revenue Per Share$0.00$0.00$0.00$0.00
EPS (Basic)-$8.70-$6.18-$7.45-$7.40
EPS (Diluted)-$8.70-$6.18-$7.45-$7.40
Shares Outstanding54.1M54.0M32.7M32.7M

Eikon Therapeutics (EIKN) financials: revenue, profit and margins

Eikon Therapeutics (EIKN) generated about $0.00 in revenue and -$322 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Eikon Therapeutics's (EIKN) revenue?+

Eikon Therapeutics generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Eikon Therapeutics profitable?+

Eikon Therapeutics reported about -$322 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with EIKN

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.08+15.03%40
HPHA.XETRHeidelberg Pharma AG
€2.01-3.37%10
MEDCL.XPARMedincell SA
€28.68+3.02%40
ZTEKZentek Ltd.
€0.33+0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.99-1.00%10
VALNValneva SE Sponsored ADR
$5.63+2.18%0
TRIBTrinity Biotech plc Sponsored ADR
$6.43-2.02%10

Held by ETFs

EIKN is in 7 US ETFs. The largest of them, with EIKN's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EIKN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.